The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status

European Journal of Cancer

Volumn 45, Issue 3, 2009, Pages 365-373

  Jover, Rodrigo ^a   Zapater, Pedro ^a   Castells, Antoni ^b   Llor, Xavier ^c,k   Andreu, Montserrat ^d   Cubiella, Joaquín ^e   Balaguer, Francesc ^b   Sempere, Laura ^a   Xicola, Rosa M ^c,k   Bujanda, Luis ^f   Reñé, Josep M ^g   Clofent, Juan ^h   Bessa, Xavier ^d   Morillas, Juan D ⁱ   Nicolás Pérez, David ^j   Pons, Elisenda ^c   Payá, Artemio ^a   Alenda, Cristina ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d HOSPITAL DEL MAR   (Spain)

^e Hospital Cristal Pinor   (Spain)

^f HOSPITAL DONOSTIA   (Spain)

^g HOSPITAL ARNAU DE VILANOVA   (Spain)

^h UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

ⁱ HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^j HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^k UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

more..

Author keywords

5 Fluorouracil; Colorectal cancer; Microsatellite instability; Prognosis; Treatment

Indexed keywords

FLUOROURACIL; GENOMIC DNA; INTERMEDIN; PROTEIN MLH1;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; COHORT ANALYSIS; COLORECTAL CANCER; DISEASE FREE SURVIVAL; DNA EXTRACTION; DRUG EFFICACY; FEMALE; FOLLOW UP; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; TUMOR CELL; TUMOR RECURRENCE;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DNA MISMATCH REPAIR; FEMALE; FLUOROURACIL; HUMANS; MALE; MICROSATELLITE INSTABILITY; NEOPLASM STAGING; PROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 59249097606     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.07.016     Document Type: Article

References (36)

1. Clark J.W., and Willet C.-G. Chemotherapy and radiation therapy of colorectal cancer. In: Rustgi A.K. (Ed). Gastrointestinal cancers. 1st ed. (2003), Saunders, Philadelphia 453-472
2. Thibodeau S.N., Bren G., and Schaid D. Microsatellite instability in cancer of the proximal colon. Science 260 (1993) 816-819
3. Wheeler J.M., Bodmer W.F., and Mortensen N.J. DNA mismatch repair genes and colorectal cancer. Gut 47 (2000) 148-153
4. Popat S., Hubner R., and Houlston R.S. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 23 (2005) 609-618
5. Elsaleh H., Joseph D., Grieu F., Zeps N., Spry N., and Iacopetta B. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 355 (2000) 1745-1750
6. Hemminki A., Mecklin J.P., Jarvinen H., Aaltonen L.A., and Joensuu H. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 119 (2000) 921-928
7. Barratt P.L., Seymour M.T., Stenning S.P., et al. DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet 360 (2002) 1381-1391
8. Carethers J.M., Smith E.J., Behling C.A., et al. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 126 (2004) 394-401
9. Lanza G., Gafa R., Santini A., Maestri I., Guerzoni L., and Cavazzini L. Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients. J Clin Oncol 24 (2006) 2359-2367
10. Ribic C.M., Sargent D.J., Moore M.J., et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. New Engl J Med 349 (2003) 247-257
11. Jover R., Zapater P., Castells A., et al. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut 55 (2006) 848-855
12. Pinol V., Andreu M., Castells A., Paya A., Bessa X., and Rodrigo J. Frequency of hereditary non-polyposis colorectal cancer and other colorectal cancer familial forms in Spain: a multicentre, prospective, nationwide study. Eur J Gastroenterol Hepatol 16 (2004) 39-45
13. Pinol V., Castells A., Andreu M., et al. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 293 (2005) 1986-1994
14. Moertel C.G., Fleming T.R., Macdonald J.S., et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. New Engl J Med 322 (1990) 352-358
15. Moertel C.G., Fleming T.R., Macdonald J.S., et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 122 (1995) 321-326
16. Wolmark N., Rockette H., Fisher B., et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 11 (1993) 1879-1887
17. Wolmark N., Rockette H., Mamounas E., et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 17 (1999) 3553-3559
18. Boland C.R., Thibodeau S.N., Hamilton S.R., et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58 (1998) 5248-5257
19. Xicola R.M., Llor X., Pons E., et al. Performance of different microsatellite marker panels for detection of mismatch repair-deficient colorectal tumors. J Natl Cancer Inst 99 (2007) 244-252
20. Elsaleh H., Powell B., McCaul K., et al. P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin Cancer Res 7 (2001) 1343-1349
21. Benatti P., Gafa R., Barana D., et al. Microsatellite instability and colorectal cancer prognosis. Clin Cancer Res 11 (2005) 8332-8340
22. Andre T., Boni C., Mounedji-Boudiaf L., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. New Engl J Med 350 (2004) 2343-2351
23. Arnold C.N., Goel A., and Boland C.R. Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer 106 (2003) 66-73
24. Carethers J.M., Chauhan D.P., Fink D., et al. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 117 (1999) 123-131
25. Meyers M., Wagner M.W., Hwang H.S., Kinsella T.J., and Boothman D.A. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res 61 (2001) 5193-5201
26. Jung B., Smith E.J., Doctolero R.T., et al. Influence of target gene mutations on survival, stage and histology in sporadic microsatellite unstable colon cancers. Int J Cancer 118 (2006) 2509-2513
27. Watanabe T., Wu T.T., Catalano P.J., et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. New Engl J Med 344 (2001) 1196-1206
28. An Q., Robins P., Lindahl T., and Barnes D.E. 5-Fluorouracil incorporated into DNA is excised by the Smug1 DNA glycosylase to reduce drug cytotoxicity. Cancer Res 67 (2007) 940-945
29. Fischer F., Baerenfaller K., and Jiricny J. 5-Fluorouracil is efficiently removed from DNA by the base excision and mismatch repair systems. Gastroenterology 133 (2007) 1858-1868
30. Fink D., Nebel S., Aebi S., et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56 (1996) 4881-4886
31. Vaisman A., Varchenko M., Umar A., et al. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance. Correlation with replicative bypass of platinum-DNA adducts. Cancer Res 58 (1998) 3579-3585
32. Bras-Goncalves R.A., Rosty C., Laurent-Puig P., Soulie P., Dutrillaux B., and Poupon M.F. Sensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status. Br J Cancer 82 (2000) 913-923
33. Fallik D., Borrini F., Boige V., et al. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res 63 (2003) 5738-5744
34. Cawkwell L., Gray S., Murgatroyd H., et al. Choice of management strategy for colorectal cancer based on a diagnostic immunohistochemical test for defective mismatch repair. Gut 45 (1999) 409-415
35. Hampel H., Frankel W.L., Martin E., et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). New Engl J Med 352 (2005) 1851-1860
36. Jover R., Paya A., Alenda C., et al. Defective mismatch-repair colorectal cancer: clinicopathologic characteristics and usefulness of immunohistochemical analysis for diagnosis. Am J Clin Pathol 122 (2004) 389-394